Simbrinza: new combination glaucoma treatment

Simbrinza (brinzolamide/brimonidine) is licensed for reducing intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension when monotherapy is inadequate.

Simbrinza is the first combination eye drop available in the UK containing a carbonic anhydrase inhibitor and an alpha2 agonist.
Simbrinza is the first combination eye drop available in the UK containing a carbonic anhydrase inhibitor and an alpha2 agonist.

PHARMACOLOGY

The carbonic anhydrase inhibitor brinzolamide reduces ocular pressure by decreasing the production of aqueous humour. Brimonidine is an alpha2 adrenergic agonist that targets receptors in the ciliary epithelium, also suppressing aqueous humour formation.1

CLINICAL STUDIES 

The safety and efficacy of a fixed-dose combination of brinzolamide 1% and brimonidine tartrate 0.2% was compared with that of brinzolamide or brimonidine monotherapy in 560 patients with open-angle glaucoma and/or ocular hypertension who had insufficient IOP reduction with their existing regimens or were receiving multiple IOP-lowering medications. All drugs were administered twice daily.2

In terms of mean change in diurnal IOP at month 3 (the primary endpoint), the combination was statistically superior to both brinzolamide (least squares mean difference: -1.4mmHg; p<0.0001) and brimonidine (least squares mean difference: -1.5mmHg; p<0.0001) as monotherapy.2

Mean percentage reductions in IOP from baseline were 26.7% to 36% with the combination, 22.4% to 27.9% with brinzolamide alone and 20.6% to 31.3% with brimonidine alone.2

A second study involving 890 patients compared the fixed-dose combination with brinzolamide and brimonidine administered individually. Mean change in diurnal IOP from baseline to month 3 with the combination drops was non-inferior to that observed with the two drugs administered separately.1

The mean reduction in IOP with the combination drops at month 3 was 8.5mmHg compared with 8.3mmHg with the separate drops.1

Safety profile

The safety profile of the combination was consistent with that of the individual components.2 The most commonly reported adverse reactions in patients treated with Simbrinza were ocular, and included hyperaemia, blurred vision, allergic-type reactions and discomfort.1

References

  1. Simbrinza Summary of Product Characteristics, July 2014.
  2. Aung T et al. Ophthalmology 2014, accepted article; doi: 10.1016/j.ophtha.2014.06.022 

View Simbrinza drug record

Further information: Alcon Laboratories 

Follow MIMS on Twitter

Sign up for MIMS bulletins


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.